This has led to a significant drive in the development and manufacture of new effective and safe biologics as the pharmaceutical industry is faced with a number of issues with current conjugation methods:

The Antibody Drug Conjugate (ADC) field is a key area within the protein and antibody engineering industry which is supported by our highly specific, stable linker technology.

Similarly, the move to follow-on biologics (Biobetters) in the therapeutic environment and improved pharmacokinetics are underpinned by stable, substitutable glycan structures.

Based on over a decade of research, our technology platforms deliver a wide range of benefits to provide a solution for the efficient and cost effective development and manufacture of new efficacious and safe biologics that improve half-life and optimize bio-availability: